QuidelOrtho Corp. Stock
QuidelOrtho Corp. Stock
QuidelOrtho Corp. shows a slight decrease today, losing -€0.200 (-0.790%) compared to yesterday.
Based on 3 Buy predictions and 2 Sell predictions the sentiment towards QuidelOrtho Corp. is rather balanced.
With a target price of 30 € there is a positive potential of 21.95% for QuidelOrtho Corp. compared to the current price of 24.6 €.
Our community identified positive and negative aspects for QuidelOrtho Corp. stock for the coming years. 1 users see the criterium "Innovation" as a plus for the QuidelOrtho Corp. stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of QuidelOrtho Corp. in the next few years
Pros
?
B****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of QuidelOrtho Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| QuidelOrtho Corp. | -0.790% | 2.500% | 26.154% | -38.191% | -41.429% | -73.548% | -85.357% |
| Veeva Systems A | -2.530% | -8.494% | -25.810% | -14.424% | -6.422% | 16.328% | -12.755% |
| Thermo Fisher Scientific Inc. | -1.250% | -0.885% | -3.923% | -2.812% | -2.393% | -9.506% | 25.280% |
| Waters Corp. | -2.270% | -1.851% | -0.090% | -8.541% | -6.046% | 4.504% | 67.889% |
Comments
QuidelOrtho (NASDAQ:QDEL) had its price target lowered by analysts at JPMorgan Chase & Co. from $26.00 to $22.00. They now have an "underweight" rating on the stock.
Show more
Ratings data for QDEL provided by MarketBeat
QuidelOrtho Co. (NASDAQ: QDEL) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $44.00 price target on the stock.
Show more
Ratings data for QDEL provided by MarketBeat
QuidelOrtho Co. (NASDAQ: QDEL) had its price target lowered by analysts at JPMorgan Chase & Co. from $38.00 to $25.00. They now have an "underweight" rating on the stock.
Show more
Ratings data for QDEL provided by MarketBeat
News
Why One Value Fund Just Bought $30 Million of a Diagnostics Stock Down 90% From Pandemic-Era Highs
On November 14, New York City-based Newtyn Management disclosed a purchase of 994,332 shares of QuidelOrtho Corporation (QDEL), increasing its stake by approximately $30.4 million.
According to a
QuidelOrtho (QDEL) Fiscal Q2 EPS Beats
QuidelOrtho (NASDAQ:QDEL), a global provider of diagnostic testing solutions, released its financial results for the quarter ended June 29, 2025, on August 5, 2025. The most notable headline was a